1 Department of Social Medicine and Population Health, Center for Healthy Communities, School of Medicine, University of California , Riverside, Riverside, California.
2 Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health , Baltimore, Maryland.
LGBT Health. 2017 Oct;4(5):315-319. doi: 10.1089/lgbt.2016.0142. Epub 2017 Sep 6.
Researchers and healthcare surveillance systems must clearly disaggregate data for transgender men and women from data for cisgender men and women to identify population-level health disparities and give every person an opportunity for cancer prevention. The limited human papillomavirus (HPV) vaccine recommendations for transgender men and women may be due to the scant literature on cancer prevalence coupled with poor understanding of HPV risks for these populations. Comprehensive cancer screening and prevention initiatives centered on relevant anatomy and sexual risk behaviors that are inclusive of transgender men and women are needed. Moreover, we need specific research to understand the impact of HPV and associated cancers on both transgender men's and women's lives.
研究人员和医疗保健监测系统必须清楚地区分跨性别男性和女性的数据与顺性别男性和女性的数据，以确定人群层面的健康差距，并为每个人提供癌症预防的机会。对跨性别男性和女性的人乳头瘤病毒 (HPV) 疫苗推荐有限，可能是由于关于癌症患病率的文献很少，再加上对这些人群的 HPV 风险的了解不佳。需要以跨性别男性和女性相关的解剖结构和性行为风险为中心的综合癌症筛查和预防计划。此外，我们还需要具体的研究来了解 HPV 和相关癌症对跨性别男性和女性生活的影响。
